RESUMO
Tacrolimus (TAC) is highly effective for the prevention of acute organ rejection. However, its clinical use may be challenging due to its large interindividual pharmacokinetic variability, which can be partially explained by genetic variations in TAC-metabolizing enzymes and transporters. The aim of this study was to evaluate the influence of genetic and clinical factors on TAC pharmacokinetic variability in 21 stable pediatric renal transplant patients. This study was nested in a previous Prograf to Advagraf conversion clinical trial. CYP3A5, ABCB1 and two POR genotypes were assessed by real-time PCR. The impact on TAC pharmacokinetics of individual genetic variants on CYP3A5 nonexpressors was evaluated by genetic score. Explicative models for TAC AUC0-24h, Cmax and Cmin after Advagraf were developed by linear regression. The built genetic scores explain 13.7 and 26.5% of the total AUC0-24h and Cmin total variability, respectively. Patients genetic information should be considered to monitorizate and predict TAC exposure.
Assuntos
Citocromo P-450 CYP3A/genética , Sistema Enzimático do Citocromo P-450/genética , Imunossupressores/farmacocinética , Imunossupressores/uso terapêutico , Tacrolimo/farmacocinética , Tacrolimo/uso terapêutico , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Criança , Feminino , Variação Genética/genética , Genótipo , Rejeição de Enxerto/tratamento farmacológico , Rejeição de Enxerto/genética , Humanos , Transplante de Rim/métodos , MasculinoRESUMO
INTRODUCTION: Zonisamide is a new-generation anticonvulsant antiepileptic drug metabolized primarily in the liver, with subsequent elimination via the renal route. OBJECTIVES: Our objective was to evaluate the utility of pharmacometabolomics in the detection of zonisamide metabolites that could be related to its disposition and therefore, to its efficacy and toxicity. METHODS: This study was nested to a bioequivalence clinical trial with 28 healthy volunteers. Each participant received a single dose of zonisamide on two separate occasions (period 1 and period 2), with a washout period between them. Blood samples of zonisamide were obtained from all patients at baseline for each period, before volunteers were administered any medication, for metabolomics analysis. RESULTS: After a Lasso regression was applied, age, height, branched-chain amino acids, steroids, triacylglycerols, diacyl glycerophosphoethanolamine, glycerophospholipids susceptible to methylation, phosphatidylcholines with 20:4 FA (arachidonic acid) and cholesterol ester and lysophosphatidylcholine were obtained in both periods. CONCLUSION: To our knowledge, this is the only research study to date that has attempted to link basal metabolomic status with pharmacokinetic parameters of zonisamide.
Assuntos
Metabolômica/métodos , Zonisamida/metabolismo , Zonisamida/farmacocinética , Adulto , Anticonvulsivantes/sangue , Anticonvulsivantes/metabolismo , Área Sob a Curva , Feminino , Voluntários Saudáveis , Humanos , Isoxazóis/sangue , Masculino , Fenômenos Farmacológicos/fisiologia , Equivalência Terapêutica , Adulto JovemRESUMO
The original version of this article contains a mistake.
RESUMO
Methotrexate (MTX) is considered the main agent for the treatment of rheumatoid arthritis (RA). Neurotoxicity is often mild, but severe encephalopathy can develop, especially with intrathecal or intravenous administration. In rare cases, this syndrome has been observed in patients on long-term low-dose oral administration. A 68-year-old male was diagnosed with RA and on treatment with oral MTX 25 mg weekly for 4 years. The patient started with progressive dysarthria, ataxia and cognitive dysfunction. Complementary tests were normal. Magnetic resonance imaging (MRI) showed hyperintense lesions in both cerebellar hemispheres on T2-weighted and FLAIR images with a diffusion restriction on diffusion-weighted imaging (DWI) and on the apparent diffusion coefficient map (ADC). On postgadolinium T1-weighted images, there were mild enhancements. Spectroscopy showed a demyelinating pattern. A pharmacogenetics determination was made, showing a heterozygous genotype in the MTHFR and ABCB1 genes. Medication with antirheumatic drug was stopped immediately on admission, and the patient gradually improved. MTX-induced leukoencephalopathy can occur even with low-dose administration. The exact pathogenic mechanism is still unknown, but it is hypothesised that it could be the result of a cumulative toxic effect on the blood-brain barrier. The nature of the relationship between the polymorphism and CNS toxicity is still unclear, and thus, further studies are warranted. Often located in the occipital lobes, the involvement of the cerebellum is quite rare. Early recognition of the condition and withdrawal of the drug lead to a better prognosis.
Assuntos
Antirreumáticos/efeitos adversos , Leucoencefalopatias/induzido quimicamente , Metotrexato/efeitos adversos , Subfamília B de Transportador de Cassetes de Ligação de ATP , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Administração Oral , Idoso , Antirreumáticos/administração & dosagem , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Encéfalo/patologia , Doenças Cerebelares/induzido quimicamente , Doenças Cerebelares/patologia , Doenças Cerebelares/fisiopatologia , Cerebelo/patologia , Imagem de Difusão por Ressonância Magnética , Humanos , Leucoencefalopatias/patologia , Leucoencefalopatias/fisiopatologia , Imageamento por Ressonância Magnética , Masculino , Metotrexato/administração & dosagem , Metotrexato/uso terapêutico , Metilenotetra-Hidrofolato Redutase (NADPH2)/genéticaRESUMO
The purpose of this investigation was to describe the characteristics of the use of systemic antifungal agents (AFAs) and to evaluate their appropriateness of use. A prospective drug-utilisation study was conducted in intensive-care areas: haematology-oncology services and transplant units. Data were collected in three periods over 9 months. The required sample size was determined to be 113 patients (margin of error ±7%, 95% confidence interval [CI]), assuming a variability of 50%. Two different investigator groups evaluated the appropriateness of use separately; Cohen's Kappa index was used to calculate the degree of agreement between groups. A total of 114 patients we included, of which 62 (54.4%) were children. A total of 150 prescriptions were administered; fluconazole was the most frequently prescribed (38%), followed by liposomal amphotericin B (22.7%) and caspofungin (18.7%). The indications were: (1) pre-emptive treatment of Candida in non-neutropaenic critically ill patients (35.1%), (2) treatment of systemic fungal infection (24.6%), (3) prophylaxis for systemic fungal infection (SFI) in immunocompromised patients (16.7%), (4) prophylaxis of SFI in transplant recipients (12.3%), (5) prophylaxis of SFI in preterm infants (5.3%), (6) treatment of SFI in neonates (6.1%). The Kappa index showed a substantial agreement (Kappa = 0.73). The indications were considered to be inappropriate in 71 (47.3%) episodes. The indications or dosages were inappropriate in 79 cases (52.7%). The indications, dosages or duration of treatment were inappropriate in 83 cases (55.3%). We conclude that AFAs are prescribed for a significant number of inappropriate indications.
Assuntos
Antifúngicos/uso terapêutico , Aspergilose/tratamento farmacológico , Candidíase/tratamento farmacológico , Uso de Medicamentos/estatística & dados numéricos , Micoses/tratamento farmacológico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anfotericina B/uso terapêutico , Antifúngicos/administração & dosagem , Aspergillus/efeitos dos fármacos , Candida/efeitos dos fármacos , Caspofungina , Criança , Pré-Escolar , Equinocandinas/uso terapêutico , Feminino , Fluconazol/uso terapêutico , Humanos , Hospedeiro Imunocomprometido , Prescrição Inadequada/estatística & dados numéricos , Lactente , Unidades de Terapia Intensiva , Lipopeptídeos , Masculino , Pessoa de Meia-Idade , Micoses/prevenção & controle , Estudos Prospectivos , Transplante , Adulto JovemRESUMO
5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This toxicity is often related to the partial or complete deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme, which causes a reduction in clearance and a longer half-life of 5-FU. It is advisable to determine if a DPD deficiency exists before administering these drugs by genotyping DPYD gene polymorphisms. The objective of this consensus of experts, in which representatives from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology participated, is to establish clear recommendations for the implementation of genotype and/or phenotype testing for DPD deficiency in patients who are candidates to receive fluoropyrimidines. The genotyping of DPYD previous to treatment classifies individuals as normal, intermediate, or poor metabolizers. Normal metabolizers do not require changes in the initial dose, intermediate metabolizers should start treatment with fluoropyrimidines at doses reduced to 50%, and poor metabolizers are contraindicated for fluoropyrimidines.
Assuntos
Capecitabina/uso terapêutico , Di-Hidrouracila Desidrogenase (NADP)/genética , Fluoruracila/uso terapêutico , Técnicas de Genotipagem/normas , Neoplasias/tratamento farmacológico , Neoplasias/genética , Seleção de Pacientes , Humanos , Polimorfismo de Nucleotídeo ÚnicoRESUMO
BACKGROUND: Moderate/severe cases of COVID-19 present a dysregulated immune system with T cell lymphopenia and a hyper-inflammatory state. This is a study protocol of an open-label, multi-center, double-arm, randomized, dose-finding phase I/II clinical trial to evaluate the safety, tolerability, alloreactivity, and efficacy of the administration of allogeneic memory T cells and natural killer (NK) cells in COVID-19 patients with lymphopenia and/or pneumonia. The aim of the study is to determine the safety and the efficacy of the recommended phase 2 dose (RP2D) of this treatment for patients with moderate/severe COVID-19. METHODS: In the phase I trial, 18 patients with COVID-19-related pneumonia and/or lymphopenia with no oxygen requirement or with an oxygen need of ≤ 2.5 liters per minute (lpm) in nasal cannula will be assigned to two arms, based on the biology of the donor and the patient. Treatment of arm A consists of the administration of escalating doses of memory T cells, plus standard of care (SoC). Treatment of arm B consists of the administration of escalating doses of NK cells, plus SoC. In the phase II trial, a total of 182 patients with COVID-19-related pneumonia and/or lymphopenia requiring or not oxygen supplementation but without mechanical ventilation will be allocated to arm A or B, considering HLA typing. Within each arm, they will be randomized in a 1:1 ratio. In arm A, patients will receive SoC or RP2D for memory T cells plus the SoC. In arm B, patients will receive SoC or RP2D for NK cells plus the SoC. DISCUSSION: We hypothesized that SARS-CoV-2-specific memory T-lymphocytes obtained from convalescent donors recovered from COVID-19 can be used as a passive cell immunotherapy to treat pneumonia and lymphopenia in moderate/severe patients. The lymphopenia induced by COVID-19 constitutes a therapeutic window that may facilitate donor engraftment and viral protection until recovery. TRIAL REGISTRATION: ClinicalTrials.gov NCT04578210 . First Posted : October 8, 2020.
Assuntos
COVID-19 , Linfopenia , Ensaios Clínicos Fase I como Assunto , Ensaios Clínicos Fase II como Assunto , Humanos , Memória Imunológica , Células Matadoras Naturais , Linfopenia/diagnóstico , Linfopenia/terapia , Estudos Multicêntricos como Assunto , Ensaios Clínicos Controlados Aleatórios como Assunto , SARS-CoV-2 , Linfócitos T , Resultado do TratamentoRESUMO
BACKGROUND: Effective treatments are still needed to reduce the severity of symptoms, time of hospitalization, and mortality of COVID-19. SARS-CoV-2 specific memory T-lymphocytes obtained from convalescent donors recovered can be used as passive cell immunotherapy. METHODS: Between September and November 2020 a phase 1, dose-escalation, single centre clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD45RA- memory T cells containing SARS-CoV-2 specific T cells as adoptive cell therapy against moderate/severe cases of COVID-19. Nine participants with pneumonia and/or lymphopenia and with at least one human leukocyte antigen (HLA) match with the donor were infused. The first three subjects received the lowest dose (1 × 105 cells/kg), the next three received the intermediate dose (5 × 105 cells/kg) and the last three received the highest dose (1 × 106 cells/kg) of CD45RA- memory T cells. Clinicaltrials.gov registration: NCT04578210. FINDINGS: All participants' clinical status measured by National Early Warning Score (NEWS) and 7-category point ordinal scales showed improvement six days after infusion. No serious adverse events were reported. Inflammatory parameters were stabilised post-infusion and the participants showed lymphocyte recovery two weeks after the procedure. Donor microchimerism was observed at least for three weeks after infusion in all patients. INTERPRETATION: This study provides preliminary evidence supporting the idea that treatment of COVID-19 patients with moderate/severe symptoms using convalescent CD45RA- memory T cells is feasible and safe. FUNDING: Clinical Trial supported by Spanish Clinical Research Network PT17/0017/0013. Co-funded by European Regional Development Fund/European Social Fund. CRIS CANCER Foundation Grant to AP-M and Agencia Valenciana de Innovación Grant AVI-GVA COVID-19-68 to BS.
RESUMO
The low prevalence of European paediatric transplanted patients and scarcity of resources and expertise led to the need for a multidisciplinary network able to improve the quality of life of paediatric patients and families requiring a solid organ or haematopoietic stem cell transplantation. The European Reference Network (ERN) TransplantChild is one of the 24 ERNs established in a European legal framework to improve the care of patients with rare diseases. ERN TransplantChild is the only ERN focused on both solid organ and haematopoietic stem cell paediatric transplantation, based on the understanding of paediatric transplantation as a complex and highly specialised process where specific complications appear regardless the organ involved, thus linking the skills and knowledge of different organ disciplines. Gathering European centres of expertise in paediatric transplantation will give access to a correct and timely diagnosis, share expertise and knowledge and collect a critical mass of patients and data that increases the speed and value of clinical research outcomes. Therefore, the ERN TransplantChild aims for a paediatric Pan-European, Pan-transplant approach.
Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Transplante de Órgãos/métodos , Europa (Continente) , Geografia , Humanos , Modelos Teóricos , Qualidade de Vida , Procedimentos Cirúrgicos OperatóriosRESUMO
OBJECTIVES: We have developed a genotyping system to determine the alleles of genes related to interindividual variability in acenocoumarol dosage requirements. This genotyping system is intended for routine clinical use and therefore it is essential that it be simple, fast and inexpensive. DESIGN AND METHODS: We developed a PCR multiplex SNaPshot reaction that targets 6 SNPs (single nucleotide polymorphisms) in CYP2C9, CYP4F2, VKORC1 and APOE genes, which are associated with acenocoumarol dose requirements. RESULTS: We tested the multiplex in 152 samples and found it to be 100% concordant with the results of other methods. CONCLUSIONS: We successfully produced a reliable multiplex system for simultaneously typing 6 SNPs. This system may be used as a model for accurate, simple and inexpensive genotyping of SNPs related to dose requirements. This information allows the prediction of drug efficiency in patients prior to treatment with acenocoumarol and the prevention of adverse drug reactions.
Assuntos
Acenocumarol/administração & dosagem , Acenocumarol/farmacocinética , Apolipoproteínas E/genética , Hidrocarboneto de Aril Hidroxilases/genética , Sistema Enzimático do Citocromo P-450/genética , Oxigenases de Função Mista/genética , Reação em Cadeia da Polimerase Multiplex/métodos , Polimorfismo de Nucleotídeo Único , Anticoagulantes/administração & dosagem , Anticoagulantes/farmacocinética , Citocromo P-450 CYP2C9 , Família 4 do Citocromo P450 , Humanos , Reação em Cadeia da Polimerase Multiplex/economia , Sensibilidade e Especificidade , Valeratos , Vitamina K Epóxido RedutasesRESUMO
Often the only available data in literature for sample size estimations in bioequivalence studies is intersubject variability, which tends to result in overestimation of sample size. In this paper, we proposed a preliminary model of intrasubject variability based on intersubject variability for Cmax and AUC data from randomized, crossovers, bioequivalence (BE) studies. From 93 Cmax and 121 AUC data from test-reference comparisons that fulfilled BE criteria, we calculated intersubject variability for the reference formulation and intrasubject variability from ANOVA. Lineal and exponential models (y=a(1-e-bx)) were fitted weighted by the inverse of the variance, to predict the intrasubject variability based on intersubject variability. To validate the model we calculated the coefficient of cross-validation of data from 30 new BE studies. The models fit very well (R2=0.997 and 0.990 for Cmax and AUC respectively) and the cross-validation correlation were 0.847 for Cmax and 0.572 for AUC. A preliminary model analyses allow us to estimate the intrasubject variability based on intersubject variability for sample size calculation purposes in BE studies. This approximation provides an opportunity for sample size reduction avoiding unnecessary exposure of healthy volunteers. Further modelling studies are desirable to confirm these results especially suggestions of the higher intersubject variability range.
Assuntos
Tamanho da Amostra , Equivalência Terapêutica , Área Sob a Curva , Estudos Cross-Over , Humanos , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
The detection and reporting of serious adverse drug reactions (SADRs) have become important components of monitoring and evaluation activities performed in hospitals. We present the implementation of a prospective pharmacovigilance program based on automatic laboratory signals (ALSs) at a hospital. We also report the general findings after the first year of operation of the program, which involved ALSs that indicate various SADRs: agranulocytosis, aplastic anemia, liver injury, thrombocytopenia, hyponatremia, and rhabdomyolysis. The number of hospitalizations during the year was 54,525, and 1,732 patients experienced at least one ALS. The review of electronic medical records (EMRs) showed that no alternative cause (i.e., no non-SADR explanation) for the ALS was identified in 520 (30%) of the patients. After the individual ALS-patient evaluation, a total of 110 SADRs (6.35% of those identified after reviewing EMRs and 21.15% of those requiring individual patient evaluations) were identified. In other words, in order to identify a single SADR, we had to review the electronic records of approximately 16 patients and personally visit 5 patients.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos/normas , Hospitalização , Laboratórios Hospitalares/normas , Desenvolvimento de Programas/normas , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/prevenção & controle , Feminino , Sistemas de Informação Hospitalar/normas , Humanos , Lactente , Recém-Nascido , Masculino , Sistemas Computadorizados de Registros Médicos/normas , Pessoa de Meia-Idade , Desenvolvimento de Programas/métodos , Estudos Prospectivos , Adulto JovemRESUMO
INTRODUCTION: The aim of this study is to establish the risk of thromboembolic events and evaluation of the use of venous thromboembolism prophylaxis in hospitalized medical patients and after discharge, and their concordance with protocols used in our hospital. MATERIAL AND METHODS: We performed a cross-sectional with prospective follow-up until hospital discharge. It included all medical patients in Internal Medicine, Pneumology and Oncology Departments. The patient's thromboembolic risk and type of thromboembolism prophylaxis indication during hospitalization and after discharge were determined. RESULTS: A total of 116 patients (52 in Internal Medicine Department, 35 in Pneumology Department and 29 in Oncology Department), with a mean age of 67 +/- 17 years (35 females; 81 males) were included. During hospitalization, 62.9% of the patients had a high risk of thromboembolic events, 3.4% a moderate risk, 23.3% low risk, and 10.3% had no risk. After discharge, these proportions were 35.6%, 3.8%, 24% and 34.6%, respectively. A total of 49.1% of the patients had an adequate indication of venous thromboembolism prophylaxis during the hospitalization and after discharge.
Assuntos
Anticoagulantes/uso terapêutico , Hospitalização , Alta do Paciente , Tromboembolia Venosa/epidemiologia , Tromboembolia Venosa/prevenção & controle , Idoso , Estudos Transversais , Uso de Medicamentos , Feminino , Humanos , Masculino , Estudos Prospectivos , Fatores de RiscoRESUMO
Introducción: En la actualidad, los concentrados de complejos protrombínicos (CCP)son usados principalmente en la reducción rápida del efecto anticoagulante producido por la administración de antagonistas de la vitamina K (AVK) en los casos de aparición de hemorragia aguda o en cirugía de urgencia, y son la mejor elección frente al uso de plasma fresco congelado (PFC). Su composición, seguridad y acción rápida en la corrección de la hemostasia (ratio internacional normalizado-INR) y en la reducción del riesgo de hemorragia hacen de éste un fármaco esencial en la práctica de urgencias y en la cirugía hospitalaria. Este trabajo valora la eficacia (coste-efectividad incremental) del empleo de CCP para normalizar el INR en la práctica habitual de un servicio de urgencias. Método: Se ha realizado un análisis coste-efectividad para el que se utilizó un modelo de simulación de Markov en Excel®(año-año), basado en un árbol de decisiones. Para la simulación probabilística se tomó el 5% del total de una población de pacientes conterapia anticoagulante oral con antivitamina K (AVK) e INR elevado en un servicio de urgencias, en ciclos anuales, durante 10 años. El CCP utilizado para el análisis ha sido Octaplex®. Resultados: El análisis de sensibilidad ha demostrado que la razón coste-efectividad incremental (RCEI) de la administración de CCP frente al uso de otras terapias para la normalización del INR es favorable al uso del CCP. Conclusiones: El uso de CCP en urgencias sería coste-efectivo (AU)
Background and objective: Prothrombin complex concentrates (PCCs) are currently used principally for rapid reduction of the anticoagulant effects of administering vitamin K in cases where acute bleeding develops or during emergency surgery. PCCs are a better choice than fresh frozen plasma in these situations. These drugs have become essential for reducing the risk of hemorrhage thanks to their composition, safety, and rapid restoration of hemostasis, specifically of the international normalized ratio (INR). This study aimed to assess the efficacy, in terms of incremental cost-effectiveness, of PCC use in restoring the INR in routine emergency department practice. Study design: For the cost-effectiveness analysis we constructed a year-by-year decision-tree (Markov model) using spreadsheet software (Excel). The probabilistic simulation sampled 5% of all emergency department patients on oral anticoagulant therapy with antivitamin K and an elevated INR in each year for 10 years. Octaplex was the PCC used in the model. Results: Sensitivity analysis showed that PCC use had a more favorable incremental cost-effectiveness ratio than did other strategies for correcting the INR. Conclusions: Use of PCCs in the emergency department would be cost-effective (AU)
Assuntos
Humanos , Protrombina/uso terapêutico , Anticoagulantes/administração & dosagem , Tratamento de Emergência/métodos , Overdose de Drogas/tratamento farmacológico , 50303 , Vitamina K/antagonistas & inibidoresRESUMO
Introducción. El objetivo de este estudio es conocer el riesgo de enfermedad tromboembólica venosa (ETV) en pacientes médicos durante su ingreso y al alta hospitalaria, y estudiar los hábitos de prescripción de tromboprofilaxis y su adecuación a los protocolos utilizados en nuestro medio. Material y método. Para ello se realizó un estudio transversal con seguimiento prospectivo hasta el alta hospitalaria. Se incluyeron pacientes médicos de los Servicios de Medicina Interna, Neumología y Oncología, en los que se determinó el grado de riesgo de ETV y el tipo de indicación de tromboprofilaxis durante el ingreso y al alta hospitalaria. Resultados. Se incluyeron 116 pacientes (52 en medicina interna, 35 en neumología y 29 en oncología), con una media de edad de 67 ± 17 años (35 mujeres; 81 hombres). En el ingreso el 62,9% tenían alto riesgo de ETV, el 3,4% moderado, el 23,3% bajo y el 10,3% no tenían riesgo. Al alta hospitalaria estos porcentajes fueron de 35,6; 3,8; 24 y 34,6%, respectivamente. La proporción de pacientes con prescripción adecuada a la indicación fue del 49,1%, tanto durante el ingreso como al alta hospitalaria (AU)
Introduction. The aim of this study is to establish the risk of thromboembolic events and evaluation of the use of venous thromboembolism prophylaxis in hospitalized medical patients and after discharge, and their concordance with protocols used in our hospital. Material and methods. We performed a cross-sectional with prospective follow-up until hospital discharge. It included all medical patients in Internal Medicine, Pneumology and Oncology Departments. The patient's thromboembolic risk and type of thromboembolism prophylaxis indication during hospitalization and after discharge were determined. Results. A total of 116 patients (52 in Internal Medicine Department, 35 in Pneumology Department and 29 in Oncology Department), with a mean age of 67 ± 17 years (35 females; 81 males) were included. During hospitalization, 62.9% of the patients had a high risk of thromboembolic events, 3.4% a moderate risk, 23.3% low risk, and 10.3% had no risk. After discharge, these proportions were 35.6%, 3.8%, 24% and 34.6%, respectively. A total of 49.1% of the patients had an adequate indication of venous thromboembolism prophylaxis during the hospitalization and after discharge (AU)